Delivoria Dafni C, Konia Eleni, Matis Ilias, Skretas Georgios
Institute of Chemical Biology, National Hellenic Research Foundation, Athens 11635, Greece.
Institute for Bio-innovation, Biomedical Sciences Research Center "Alexander Fleming", Vari 16672, Greece.
ACS Synth Biol. 2025 Jun 20;14(6):2283-2293. doi: 10.1021/acssynbio.5c00166. Epub 2025 May 12.
Protein misfolding and aggregation are central features of a wide range of diseases, including neurodegenerative disorders, systemic amyloidoses, and cancer. The identification of compounds that can modulate protein folding and aggregation is a key step toward developing effective therapies. High-throughput screening methods are essential for efficiently identifying such compounds. In this study, we optimized a previously developed high-throughput genetic screen for monitoring protein misfolding and aggregation in bacteria. This system is based on monitoring the fluorescence of cells expressing fusions of human misfolding-prone and disease-related proteins (MisPs) with the green fluorescent protein. We systematically tested a variety of experimental conditions, such as overexpression conditions and MisP-GFP fusion formats, to identify key parameters that affect the sensitivity and dynamic range of the assay. Using misfolding-prone, cancer-associated variants of human p53 as a model system, we found that strong overexpression conditions, such as high copy number vectors, strong promoters, high inducer concentrations, and high overexpression temperatures, can yield optimal assay performance. These optimized assay conditions were also validated with additional MisPs, such as the Alzheimer's disease-associated amyloid-β peptide and variants of superoxide dismutase 1 associated with amyotrophic lateral sclerosis. At the same time, we observed that certain conditions, such as inducer concentrations and overexpression temperature, may need to be precisely fine-tuned for each new MisP target to yield optimal assay performance. Our findings provide a framework for standardizing MisP-GFP screening assays, facilitating their broad application in the discovery of therapeutic agents targeting protein misfolding and aggregation.
蛋白质错误折叠和聚集是包括神经退行性疾病、全身性淀粉样变性和癌症在内的多种疾病的核心特征。鉴定能够调节蛋白质折叠和聚集的化合物是开发有效疗法的关键一步。高通量筛选方法对于高效鉴定此类化合物至关重要。在本研究中,我们优化了先前开发的用于监测细菌中蛋白质错误折叠和聚集的高通量遗传筛选方法。该系统基于监测表达易发生错误折叠的人类疾病相关蛋白(MisPs)与绿色荧光蛋白融合体的细胞的荧光。我们系统地测试了各种实验条件,如过表达条件和MisP-GFP融合形式,以确定影响该检测灵敏度和动态范围的关键参数。以人类p53的易发生错误折叠的癌症相关变体作为模型系统,我们发现强过表达条件,如高拷贝数载体、强启动子、高诱导剂浓度和高过表达温度,可产生最佳检测性能。这些优化的检测条件也通过其他MisPs进行了验证,如与阿尔茨海默病相关的淀粉样β肽和与肌萎缩侧索硬化相关的超氧化物歧化酶1变体。同时,我们观察到某些条件,如诱导剂浓度和过表达温度,可能需要针对每个新的MisP靶点进行精确微调,以产生最佳检测性能。我们的研究结果为标准化MisP-GFP筛选检测提供了一个框架,有助于其在发现针对蛋白质错误折叠和聚集的治疗药物方面的广泛应用。